|
KMID : 0043320150380122120
|
|
Archives of Pharmacal Research
2015 Volume.38 No. 12 p.2120 ~ p.2123
|
|
|
Cabozantinib for the treatment of non-small cell lung cancer with KIF5B-RET fusion. An example of swift repositioning
|
|
Song Min-Soo
Kim Seong-Heon
Yoon Suk-Kyoon
|
|
|
Abstract
|
|
|
|
A new chimeric fusion transcript of KIF5B (the kinesin family 5B gene) and the RET (Rearranged during Transcription) oncogene, KIF5B-RET, was found in 1?2 % of lung adenocarcinomas (LADCs) in 2012. Several related clinical trials for non-small cell lung cancer (NSCLC) with KIF5B-RET rearrangements using existing RET inhibitors, such as cabozantinib, lenvatinib, vandetanib, sunitinib, ponatinib, and AUY922, have been swiftly initiated by the discovery of the KIF5B-RET fusion gene. Anti-RET activity and the status of clinical development of cabozantinib for KIF5B-RET fusion-positive NSCLC are discussed.
|
|
|
KEYWORD
|
|
|
Cabozantinib, KIF5B-RET, Lung cancer, Non-small cell lung cancer, Adenocarcinoma, Small-molecule tyrosine kinase inhibitor
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|